{"id":24377,"date":"2025-04-13T17:41:36","date_gmt":"2025-04-13T17:41:36","guid":{"rendered":"https:\/\/researchchemicalstore.eu\/?post_type=product&#038;p=24377"},"modified":"2025-10-21T12:47:48","modified_gmt":"2025-10-21T12:47:48","slug":"maxtc-5-mapb-4-fma-5-meo-mipt","status":"publish","type":"product","link":"https:\/\/researchchemicalstore.eu\/et\/product\/maxtc-5-mapb-4-fma-5-meo-mipt\/","title":{"rendered":"MaXTC 5-MAPB\/4-FMA\/5-MeO-MiPT"},"content":{"rendered":"<h1><strong>Toote definitsioon: MaXTC 5-MAPB \/ 4-FMA \/ 5-MeO-MiPT graanulid<\/strong><\/h1>\n<p class=\"ds-markdown-paragraph\"><strong>Koostis graanuli kohta (mikrokapseldatud):<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>5-MAPB (5-metoks\u00fc-3,4-met\u00fcleendioks\u00fcamfetamiin):<\/strong>\u00a060 mg<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>4-FMA (4-fluorometamfetamiin):<\/strong>\u00a040 mg<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>5-MeO-MiPT (5-metoks\u00fc-N-met\u00fc\u00fcl-N-isoprop\u00fc\u00fcltr\u00fcptamiin):<\/strong>\u00a05 mg<br \/>\n<strong>Vorm:<\/strong>\u00a0\u00dchtlased, aeglaselt vabanevad graanulid<br \/>\n<strong>V\u00e4limus:<\/strong>\u00a0Heleda v\u00e4rvusega \u00fcmmargused tabletid (iga\u00fcks \u00b1 220 mg)<br \/>\n<strong>CAS-numbrid:<\/strong><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">5-MAPB: 1354631-79-7<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">4-FMA: 351-03-1<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">5-MeO-MiPT: 96096-55-8<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Kirjeldus ja toimemehhanism<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\"><strong>MaXTC<\/strong>\u00a0on\u00a0<strong>v\u00f5imas, tasakaalustatud entaktogeenne ja stimuleeriv segu<\/strong>, mis on loodud a\u00a0<strong>empaatia, energia ja kergete ps\u00fchhedeelsete efektide kombinatsioon<\/strong>.<\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>5-MAPB<\/strong>\u00a0\u279c Esmane\u00a0<strong>serotonergiline empatogeenne toime<\/strong>\u00a0(sarnane MDMA-ga, aga leebem)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>4-FMA<\/strong>\u00a0\u279c\u00a0<strong>Dopamiinergiline\/noradrenergiline stimulant<\/strong>\u00a0energia ja keskendumisv\u00f5ime saamiseks<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>5-MeO-MiPT<\/strong>\u00a0\u279c\u00a0<strong>Kerge ps\u00fchhedeelne toon<\/strong>\u00a0(sensoorne v\u00f5imendus, emotsionaalne s\u00fcgavus)<\/p>\n<\/li>\n<\/ul>\n<h3><strong>Peamised m\u00f5jud:<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\">\u2714 Tugev\u00a0<strong>emotsionaalne side<\/strong>\u00a0(MDMA-laadne)<br \/>\n\u2714 Pikaajaline\u00a0<strong>f\u00fc\u00fcsiline energia<\/strong>\u00a0ilma terava kokkup\u00f5rketa<br \/>\n\u2714 Peen\u00a0<strong>visuaalne ja kombatav tugevdamine<\/strong><br \/>\n\u2714\u00a0<strong>V\u00e4hem l\u00f5ualuude kokkusurumist<\/strong>\u00a0kui puhaste stimulantidega<\/p>\n<hr \/>\n<h2><strong>Kasutusjuhud ja rakendused<\/strong><\/h2>\n<h3><strong>1. Sotsiaalne ja pidulik kasutamine<\/strong><\/h3>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Festivalid, klubid ja peod<\/strong>\u00a0\u2013 Pikaajaline energia + empaatia.<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>S\u00fcgavad vestlused ja \u00fchendus<\/strong>\u00a0\u2013 V\u00e4hem \u00fcle j\u00f5u k\u00e4iv kui puhas MDMA.<\/p>\n<\/li>\n<\/ul>\n<h3><strong>2. Terapeutilised v\u00f5imalused (eksperimentaalsed)<\/strong><\/h3>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\">V\u00f5imalik, et kasulik\u00a0<strong>emotsionaalne t\u00f6\u00f6tlemine<\/strong>\u00a0(kliiniliselt pole uuritud).<\/p>\n<\/li>\n<\/ul>\n<h3><strong>3. Uurimist\u00f6\u00f6 eesm\u00e4rgid<\/strong><\/h3>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\">Uuring teemal\u00a0<strong>Entaktogeenide, stimulantide ja tr\u00fcptamiinide kombineeritud toime<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>MaXTC pelletite eelised<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\">\u2705\u00a0<strong>Tasakaalustatud \u201eTrifecta\u201d tegevus<\/strong><br \/>\n\u2192 Empaatia (5-MAPB) + Energia (4-FMA) + Sensoorne s\u00fcgavus (5-MeO-MiPT)<\/p>\n<p class=\"ds-markdown-paragraph\">\u2705\u00a0<strong>Pikem toimeaeg (~6-8 tundi)<\/strong><br \/>\n\u2192 Vaja on v\u00e4hem korduvaid annuseid.<\/p>\n<p class=\"ds-markdown-paragraph\">\u2705\u00a0<strong>V\u00e4hem &quot;kokkuv\u00f5tet&quot; kui MDMA-l<\/strong><br \/>\n\u2192 T\u00e4nu j\u00e4rkj\u00e4rgulisele vabanemisele.<\/p>\n<p class=\"ds-markdown-paragraph\">\u2705\u00a0<strong>T\u00e4pselt doseeritud<\/strong><br \/>\n\u2192 V\u00e4hendab \u00fcledoosi ohtu.<\/p>\n<hr \/>\n<h2><strong>Puudused ja riskid<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\">\u274c\u00a0<strong>Kliinilised andmed puuduvad<\/strong>\u00a0\u2192 Tundmatud pikaajalised riskid.<br \/>\n\u274c\u00a0<strong>V\u00f5imalikud k\u00f5rvaltoimed:<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>S\u00fcdamepekslemine<\/strong>\u00a0(4-FMA poolt)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Kerge \u00e4revus<\/strong>\u00a0(5-MeO-MiPT suuremates annustes)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Deh\u00fcdratsioon<\/strong>\u00a0(stimuleeriva toime t\u00f5ttu)<br \/>\n\u274c\u00a0<strong>Potentsiaalselt s\u00f5ltuvust tekitav<\/strong>\u00a0\u2192 4-FMA dopamiiniefekt v\u00f5ib p\u00f5hjustada iha.<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Soovitatav annus ja kasutamine<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\">\u26a0\u00a0<strong>Hoiatus:<\/strong>\u00a0Ainult uurimisotstarbel.\u00a0<strong>Mitte inimtoiduks.<\/strong><\/p>\n<div class=\"markdown-table-wrapper\">\n<table>\n<thead>\n<tr>\n<th>Eesm\u00e4rk<\/th>\n<th>Annustamine<\/th>\n<th>M\u00f5ju kestus<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Kerged m\u00f5jud<\/strong><\/td>\n<td>\u00bd pelletit (~ 30 mg 5-MAPB \/ 20 mg 4-FMA \/ 2,5 mg 5-MeO-MiPT)<\/td>\n<td>5-6 tundi<\/td>\n<\/tr>\n<tr>\n<td><strong>Standardne annus<\/strong><\/td>\n<td><strong>1 pellet (60\/40\/5mg)<\/strong><\/td>\n<td>6-8 tundi<\/td>\n<\/tr>\n<tr>\n<td><strong>Kogenud kasutajad<\/strong><\/td>\n<td>Maks.\u00a0<strong>1,5 pelletit (90\/60\/7,5 mg)<\/strong><\/td>\n<td>8+ tundi (ei ole soovitatav algajatele)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ds-markdown-paragraph\"><strong>Haldus:<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Ainult suu kaudu<\/strong>\u00a0(\u00e4rge nuusutage\/s\u00fcstige).<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Operatsioon algab p\u00e4rast\u00a0<strong>~45\u201360 minutit<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\"><strong>N\u00f5uanded ohutuks kasutamiseks:<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>H\u00fcdreeri<\/strong>\u00a0(kuid mitte liialdatud).<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Tehke pause<\/strong>\u00a0(v\u00e4hemalt 4\u20136 n\u00e4dalat kasutuskordade vahel).<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Kasutage turvalises keskkonnas<\/strong>\u00a0(eelistatavalt koos reisijuhiga).<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Korduma kippuvad k\u00fcsimused (KKK)<\/strong><\/h2>\n<h3><strong>1. Kas MaXTC on Hollandis seaduslik?<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\">\u2192\u00a0<strong>T\u00f5en\u00e4oliselt ebaseaduslik<\/strong>\u00a0oopiumiseaduse alusel (k\u00f5ik komponendid on reguleeritud v\u00f5i halli ala).<\/p>\n<h3><strong>2. Mille poolest see tavalisest ecstasyst\/MDMA-st erineb?<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\">\u2192\u00a0<strong>V\u00e4hem eufooriline, aga tasakaalukam<\/strong>\u00a0(v\u00e4hem \u201eveeremist\u201c, paremini kontrollitud energia).<\/p>\n<h3><strong>3. Kas ma saan seda koos alkoholi v\u00f5i teiste uimastitega v\u00f5tta?<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\">\u2192\u00a0<strong>Absoluutselt ei soovita!<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Alkohol<\/strong>\u00a0\u2192 Suurenenud deh\u00fcdratsioon\/toksilisus.<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Ps\u00fchhoaktiivsed ained<\/strong>\u00a0\u2192 Ettearvamatud interaktsioonid.<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>MAO inhibiitorid<\/strong>\u00a0\u2192\u00a0<strong>\u00c4\u00e4rmiselt ohtlik!<\/strong><\/p>\n<\/li>\n<\/ul>\n<h3><strong>4. Kas on olemas serotoniinis\u00fcndroomi oht?<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\">\u2192\u00a0<strong>Teoreetiliselt v\u00f5imalik<\/strong>\u00a05-MAPB + 5-MeO-MiPT kombinatsiooni abil \u2192\u00a0<strong>Mitte kombineerida SSRI-de\/MAO inhibiitoritega!<\/strong><\/p>\n<h3><strong>5. Milline on allak\u00e4ik?<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\">\u2192\u00a0<strong>Leebem kui MDMA<\/strong>\u00a0(v\u00e4hem emotsionaalset langust, aga mingi kogemus)\u00a0<strong>kerge v\u00e4simus\/uneh\u00e4ired<\/strong>.<\/p>\n<hr \/>\n<h2><strong>Laboriaruanne ja kvaliteedikontroll<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\"><strong>Standardpartii anal\u00fc\u00fcs:<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Puhtus:<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\">5-MAPB: \u226597%<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">4-FMA: \u226595%<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">5-MeO-MiPT: \u226598%<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>J\u00e4\u00e4nud lahustid:<\/strong>\u00a0&lt;1%<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Annuse j\u00e4rjepidevus:<\/strong>\u00a0\u00b13% variatsioon pelleti kohta<\/p>\n<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\"><strong>Stabiilsus:<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>S\u00e4ilivusaeg:<\/strong>\u00a0<strong>18\u201324 kuud<\/strong>\u00a0(hoida jahedas, pimedas ja kuivas kohas).<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Kokkuv\u00f5te ja ohutusn\u00f5uanded<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\"><strong>MaXTC<\/strong>\u00a0on\u00a0<strong>v\u00f5imas, mitmek\u00fclgne segu<\/strong>\u00a0neile, kes otsivad\u00a0<strong>alternatiiv traditsioonilistele empatogeenidele<\/strong>, aga t\u00e4nu\u00a0<strong>tundmatud riskid<\/strong>\u00a0on\u00a0<strong>\u00e4\u00e4rmine ettevaatus<\/strong>\u00a0pakutud.<\/p>\n<p class=\"ds-markdown-paragraph\">\u26a0\u00a0<strong>LAHTI\u00dcTLUS:<\/strong>\u00a0See toode on\u00a0<strong>ainult uurimisotstarbel<\/strong>\u00a0ja\u00a0<strong>ei ole ette n\u00e4htud inimtoiduks<\/strong>.<a href=\"https:\/\/researchchemicalstore.eu\/et\/pood\/iboga-ibogaiin\/osta-ibogaine-hcl-veebist\/\">osta ibogaine hcl veebist<\/a><a href=\"https:\/\/researchchemicalstore.eu\/et\/pood\/iboga-ibogaiin\/iboga-juure-koor\/\">iboga juure koor<\/a><a href=\"https:\/\/researchchemicalstore.eu\/et\/pood\/lusergamiidid\/1-cp-lsd-2\/\">1 cp lsd<\/a><a href=\"https:\/\/researchchemicalstore.eu\/et\/pood\/graanulid-graanulite-jaoks\/o-dsmt-50mg-graanulid\/\">o-dsmt<\/a><a href=\"https:\/\/researchchemicalstore.eu\/et\/pood\/lusergamiidid\/1vlsd\/\">1vlsd<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Toote m\u00e4\u00e4ratlus: MaXTC 5-MAPB \/ 4-FMA \/ 5-MeO-MiPT graanulid Koostis graanuli kohta (mikrokapseldatud): 5-MAPB (5-metoks\u00fc-3,4-met\u00fcleendioks\u00fcamfetamiin): 60 mg 4-FMA (4-fluorometamfetamiin): 40 mg 5-MeO-MiPT (5-metoks\u00fc-N-met\u00fc\u00fcl-N-isoprop\u00fc\u00fcltr\u00fcptamiin): 5<\/p>","protected":false},"featured_media":28809,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[459,460,383,433,436,434,339,322,333,467,468,324,381],"product_tag":[664,326],"class_list":{"0":"post-24377","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-4fma-kopen","7":"product_cat-4-fma-pellets","8":"product_cat-5-mapb","9":"product_cat-5-mapb-pellets","10":"product_cat-5-meo-mipt","11":"product_cat-5-meo-mipt-pellets","12":"product_cat-benzofuran","13":"product_cat-bijna-verboden","14":"product_cat-gefluoreerden","15":"product_cat-maxtc","16":"product_cat-maxtc-pellets","17":"product_cat-pellets-for-pellet","18":"product_cat-tryptamines","19":"product_tag-maxtc","20":"product_tag-nl","22":"first","23":"instock","24":"taxable","25":"shipping-taxable","26":"purchasable","27":"product-type-variable"},"_links":{"self":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product\/24377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/comments?post=24377"}],"version-history":[{"count":4,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product\/24377\/revisions"}],"predecessor-version":[{"id":26501,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product\/24377\/revisions\/26501"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/media\/28809"}],"wp:attachment":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/media?parent=24377"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product_brand?post=24377"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product_cat?post=24377"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product_tag?post=24377"}],"curies":[{"name":"t\u00f6\u00f6leht","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}